CD4 and acute myeloid leukemia: Decitabine treatment depleted MDSC populations (Gr1+/CD11b+) in normal (BALB/c), mouse AML (WEHI-3 cells in BALB/c) and lymphoma (EL4 cells in C57/BL6) mice models with minimal changes to other immune effector cells (CD4+ T cells, CD8+ T cells, NK cells, B cells, Tregs, and DCs).